High Specific Activity Preparation of F-18 Tetrafluoroborate

ABSTRACT

Embodiments of the invention provide methods of synthesizing 18F-tetrafluoroborate (18F-TFB) via direct radiofluorination on boron trifluoride (BF3) to enhance both labeling yield and specific activity. Uses of 18F-TFB include imaging of thyroid or breast cancer, and imaging of thyroid, breast, stomach, salivary glands or kidney.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent application Ser. No. 16/095,865 filed Oct. 23, 2018, which is a 371 application of PCT/US2017/029089, filed Apr. 24, 2017, which claims priority to U.S. Provisional Application No. 62/327,134 filed on Apr. 25, 2016, which are all incorporated by reference in their entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

Not Applicable.

BACKGROUND

The sodium/iodide symporter (NIS) is an intrinsic membrane glycoprotein, which mediates the uptake of iodide in the thyroid gland and other NIS expressing cells or tissues [Ref. 1-3]. The active transport of iodide is the basis for the diagnosis and therapeutic treatment of thyroid disease and thyroid cancer. The clinical application of radioiodine also builds the foundation of modern nuclear medicine [Ref. 4]. The identification and characterization of human NIS (hNIS) in 1996 [Ref. 5, 6] created new opportunities for the use of hNIS as a reporter gene in viral therapy investigations and imaging of cell migration and differentiation. Despite considerable success in single photon imaging of the thyroid and thyroid cancers with ¹²³I, ¹³¹I, or [^(99m)Tc]pertechnetate [Ref. 2, 3], there remain obvious limitations for use of these radioisotopes for diagnostic imaging. Both ¹²³I (T_(1/2)=13.13 hours) and ¹³¹I (T_(1/2)=8.02 d) are true iodine imaging radiotracers, but have longer half lives than required for a diagnostic study, which result in unnecessarily high dose of irradiation to patients and staff. [^(99m)Tc]pertechnetate (T_(1/2)=6 hours) has found use as a radioiodine analog in thyroid diseases [Ref. 7, 8], and has suitable properties for single photon emission computed tomography (SPECT). Nevertheless, SPECT has the limited resolution and sensitivity, especially in detection of small metastases and low volume diseases. Positron emission tomography (PET) has significantly better sensitivity and quantitative accuracy than SPECT, particularly for accumulations in small regions. The positron emitter ¹²⁴I (T_(1/2)=4.2 d) has been used in NIS imaging [Ref. 9].

However, the unnecessarily long half-life of ¹²⁴I and its complex emission properties that include high energy gamma photons are drawbacks for diagnostic imaging applications. Also, the production of ¹²⁴I requires specialized solid target systems which are not available in most cyclotron facilities [Ref. 10]. Positron emitting ¹⁸F-fluoride ([¹⁸F], T_(1/2)=109.7 min) is the most commonly employed radioisotope for PET imaging. It has favorable physical decay properties of 97% positron emission and low positron energy (β+max=0.635 MeV) and is produced by all PET cyclotrons. The development of ¹⁸F-fluoride based PET tracers for NIS imaging would be encouraging. Since various anions (e.g., I⁻, SeCN⁻, SCN⁻, ReO₄ ⁻, TcO₄ ⁻, NO₃ ⁻) are transported by NIS [Ref. 6], the critical physicochemical features of these well transported substrates is anionic monovalency with similar size and space-filling properties as the iodide ion. Before the advent of clinical PET, in 1950s and early 1960s, Anbar et al. [Ref 11, 12] reported that the tetrafluoroborate (TFB, BF₄ ⁻) anion was effective to inhibit thyroid uptake of iodide ion. These researchers also showed that [¹⁸F] labeled TFB, synthesized from reactor produced ¹⁸F-fluoride, specifically accumulated in rat thyroid. The initial labeling of TFB was accomplished by an ion exchange reaction of KBF₄ in acid at room temperature or heating to make ¹⁸F-TFB, and the potassium salt was purified by recrystallization after neutralization [Ref. 13]. The isotopic exchange labeling approach inherently results in low specific activity ¹⁸F-TFB. Recently, Jauregui-Osoro et al. [Ref. 14] updated the labeling of ¹⁸F-TFB using current ¹⁸F-fluoride production and purification methods. With the same mechanism, ¹⁸F-TFB was synthesized in mixture of 1 mg NaBF₄ and 1.5 N HCl at 120° C. After filtration through a Dionex AG cartridge (a cation exchange cartridge loaded with silver ions) and alumina cartridge, ¹⁸F-TFB of >96% radiochemical purity was obtained in approximately 10% yield. The specific activity was ˜1 GBq/μmol with starting activities of 12-18 GBq of ¹⁸F-fluoride [Ref 14]. PET/CT imaging in normal mice with transgenic thyroid tumors showed ¹⁸F-TFB to delineate uptake in normal tissues expressing NIS (thyroid, stomach, salivary glands) and enhanced uptake in thyroid tumor. Researchers from the same institution also showed that ¹⁸F-TFB was effective as a NIS probe in the NIS-transfected colon carcinoma cell line, HCT116 [Ref. 15]. However, as pointed out by Youn et al. [Ref. 16], specific activities achieved by the reported method are substantially lower than those typically required for receptor-mediated radiopharmaceuticals (˜30 GBq/mmol). Therefore, there is a need for synthesis of ¹⁸F-TFB with higher specific activity.

SUMMARY OF THE INVENTION

The present disclosure describes in one aspect a method of radiolabeling tetrafluoroborate (TFB) with ¹⁸F-fluoride, the method comprising direct radiofluorination on boron trifluoride (BF₃) by reacting the BF₃ directly with ¹⁸F-fluoride.

In another aspect the present disclosure provides a method of radiolabeling tetrafluoroborate with ¹⁸F-fluoride, the method comprising: (a) reacting ¹⁸F-fluoride with BF₃; and (b) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃. In some aspects, the ¹⁸F-fluoride is trapped on an anion exchange cartridge and the reacting of step (a) of ¹⁸F-fluoride with BF3 is performed on the anion exchange cartridge.

In another aspect, the method of radiolabeling tetrafluoroborate with [¹⁸F]fluoride, the method consisting essentially of: (a) trapping ¹⁸F-fluoride on an anion exchange column; (b) reacting [¹⁸F]fluoride with BF₃; and (c) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃ from the anion exchange column, wherein the resultant ¹⁸F-TFB has a specific activity of at least 5 GBq/μmol.

In another aspect, a high specific activity preparation of ¹⁸F-tetrafluoroborate is provided. The high specific activity preparation is prepared by the methods disclosed herein. In some aspects, the preparation has at least 95% radiochemical purity. In some aspects, the specific activity is at least 8 GBq/μmol.

In yet another aspect, methods of use of the high specific activity preparation of ¹⁸F-tetrafluoroborate are provided. Suitable uses include, for example, imaging the thyroid, breast, stomach, salivary glands or kidneys of a subject. Other suitable uses include imaging of thyroid or breast cancer in a subject. Another suitable use is for monitoring gene therapies that employ the hNIS reporter gene.

These and other features, aspects, and advantages of the present invention will become better understood upon consideration of the following detailed description, drawings, and appended claims.

DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic showing the preparation of BF₃.THF/PE complex solution.

FIG. 1B is a schematic of an alternative simplified method of preparing BF₃.THF/PE complex solution.

FIG. 2 is a depiction of the in-house-made Lewatit® MP-64 cartridge.

FIG. 3 is a schematic of automated module for the preparation of ¹⁸F-TFB. Valves V1-V5 are composed of a single-use cassette that is mounted to the front of the module. All other valves are non-disposable Teflon diaphragm solenoid valves.

FIG. 4 depicts the relationship of radiochemical yields (uncorrected) to the amount of unlabeled BF₄-produced as found using different amounts of MP-64 resin to pre-filter the BF₃.THF/PE reagent (data from Table 1).

FIG. 5 is a graph showing radio-TLC of purified ¹⁸F-TFB (Rf=0.8-0.85) with the silica gel stationary phase and methanol mobile phase. If present, unreacted ¹⁸F-fluoride would remain at the origin.

FIG. 6A depicts HPLC analysis of the ¹⁸F-TFB product in saline, conductivity data for 10 μg/mL NaF standard.

FIG. 6B depicts HPLC analysis of the ¹⁸F-TFB product in saline, conductivity data for 10 μg/mL NaBF4 standard.

FIG. 6C depicts HPLC analysis of the ¹⁸F-TFB product in saline, radioactivity data for 1.1 MBq ¹⁸F-fluoride standard.

FIG. 6D depicts HPLC analysis of the ¹⁸F-TFB product in saline, conductivity data for purified ¹⁸F-TFB in saline.

FIG. 6E depicts HPLC analysis of the ¹⁸F-TFB product in saline, radioactivity data for purified ¹⁸F-TFB in saline.

FIG. 7 shows GC analysis of residual organic solvents in the final ¹⁸F-TFB product. No obvious petroleum ether peaks were observed.

FIG. 8 is a schematic of the putative reaction scheme for formation of ¹⁹F/¹⁸F-TFB from BF₃ of the preparation of BF₃.THF/PE complex solution.

FIG. 9A is a graph depicting time dependence of ¹⁸F-TFB uptake (SUV) in different organs in representative hNIS-expressing C6 glioma xenografted mice at high specific activity of ¹⁸F-TFB (13 MBq/μmol or 0.37 mg/kg mouse weight).

FIG. 9B is a graph depicting time dependence of ¹⁸F-TFB uptake (SUV) in different organs in representative hNIS-expressing C6 glioma xenografted mice at low specific activity of ¹⁸F-TFB (3 MBq/μmol or 1.6 mg/kg mouse weight).

FIG. 10 depicts PET images of ¹⁸F-TFB distribution in control mouse (left) and a mouse bearing hNIS-positive and hNIS-negative C6 glioma xenografts (right). The overlaid reference bone atlas is computer generated.

FIG. 11A depicts dependence of tumor of ¹⁸F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice.

FIG. 11B depicts dependence of stomach of ¹⁸F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice.

FIG. 11C depicts dependence of tumor/stomach ratio of ¹⁸F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice. The tumor/stomach ratio data for administered mass >0.5 mg/kg was fit to a bi-exponential clearance model using non-linear least-squares regression. Microsoft Excel Solver was used to regress the tumor/stomach ratios using a nonlinear least-squares regression algorithm.

FIG. 12 are pictures representing immunostaining of hNIS-expressing C6 glioma xenografts (10× magnification) showing intra-tumoral and inter-tumoral variability of expression of hNIS. (Green: Alexa Fluor 488 antibody bound hNIS and Blue: DAPI stained nuclei)

FIG. 13 is a schematic representation of the imaging protocol. Patients were screened on day 1 and imaged by ¹⁸F-TFB PET/CT on day 2.

FIG. 14 depicts a graph showing time-activity curves of ¹⁸F-TFB in healthy mail participant. LVBP=left-ventricular blood pool.

FIG. 15A are coronal PET/CT images of ¹⁸F-TFB in healthy male participants at 2 hours post-injection (p.i.). Physiologic distribution of ¹⁸F-TFB is seen in thyroid, salivary glands, stomach and intestines. Prominent excretion of radioactivity is seen in urinary bladder.

FIG. 15B are coronal PET/CT images of ¹⁸F-TFB in healthy female participants at 2 hours post-injection. Physiologic distribution of ¹⁸F-TFB is seen in thyroid, salivary glands, stomach and intestines. Prominent excretion of radioactivity is seen in urinary bladder.

DETAILED DESCRIPTION

Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

The following discussion is presented to enable a person skilled in the art to make and use embodiments of the invention. Various modifications to the illustrated embodiments will be readily apparent to those skilled in the art, and the generic principles herein can be applied to 7 other embodiments and applications without departing from embodiments of the invention. Thus, embodiments of the invention are not intended to be limited to embodiments shown, but are to be accorded the widest scope consistent with the principles and features disclosed herein. The following detailed description is to be read with reference to the figures, in which like elements in different figures have like reference numerals. The figures, which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of embodiments of the invention. Skilled artisans will recognize the examples provided herein have many useful alternatives and fall within the scope of embodiments of the invention.

A method of radiolabeling tetrafluoroborate (TFB) with ¹⁸F-fluoride is provided. The method comprises the direct radiofluorination on boron trifluoride (BF₃) by reacting the BF₃ directly with ¹⁸F-fluoride. This method provides ¹⁸F-TFB with an enhanced labeling yield and higher specific activity.

In some embodiments, the method comprises (a) reacting ¹⁸F-fluoride with BF₃; and (b) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃. In some embodiments, the ¹⁸F-fluoride is trapped on an anion exchange cartridge or column and the reacting of step (a) of ¹⁸F-fluoride with BF₃ is performed on the anion exchange cartridge or column. In this method, the reacted ¹⁸-TFB remains on the anion exchange cartridge or column to be separated from the unreacted ¹⁸F-fluoride and BF₃.

Suitable anion exchange columns or cartridges are known in the art. For example, in some embodiments, the anion exchange cartridge is a quaternary methyl ammonium anion exchange (QMA) cartridge. Suitable anion exchange resins will have a sufficient affinity for ¹⁸F-TFB as to be able to separate the ¹⁸F-TFB from the unreacted ¹⁸F-fluoride and BF₃.

In some embodiments, the anion exchange cartridge or column containing the ¹⁸F-TFB is washed at least once to remove the unreacted BF₃ and residual solvent from the cartridge. The anion exchange cartridge or column may be washed with a suitable wash solution. Suitable wash solutions include, but not limited to, for example, THF and/or water to remove the unreacted BF₃ and residual solvent. In some embodiments, the wash solution comprises ether. In some embodiments, the cartridge or column is washed at least one, at least twice, at least three times. In some embodiments, the column is first washed with THF and then washed with distilled water. In another embodiment, the column is washed sequentially with THF and water. In some embodiments, the column is washed with about 10 mL of THF followed by 10 mL of water.

The ¹⁸F-TFB is eluted from the anion exchange column. In some embodiments, the ¹⁸F-TFB is eluted using saline. In other embodiments, the ¹⁸F-TFB is eluted with solution selected from the group consisting of phosphate buffer saline (PBS), sodium citrate, sodium chloride and sodium bicarbonate. Suitable concentrations of saline for removal of the ¹⁸F-TFB are known in the art and include, but are not limited to, about 0.9% NaCl.

The eluted crude ¹⁸F-TFB may be further purified by passing through a second column or cartridge comprising alumina with a neutral surface chemistry. Suitable columns or cartridges include, but are not limited to, for example, alumina-N SepPak® Plus cartridge (SepPak®). The second column or cartridge is used to remove unreacted ¹⁸F-fluoride from the solution. The eluted crude ¹⁸F-TFB may be passed over at least one second column or cartridge. In some embodiments, the eluted crude ¹⁸F-TFB may be passed over at least two second column or cartridges. In some embodiments, the eluted crude ¹⁸F-TFB may be passed over at least three second column or cartridges. In some embodiments, the eluted ¹⁸F-TFB is passage through a sterilizing filter. In some embodiments, the sterilizing filter is 0.2 μM.

For the methods provided herewith, BF₃ may be provided in a solution of BF₃.THF complex in petroleum ether. BF₃.THF may be produced by methods known in the art, for example, from BF₃ gas dissolved in THF using petroleum ether. In some instances, the BF₃.THF complex was filtered to remove BF⁴⁻ before reacting with ¹⁸F-fluoride. In some embodiments, the BF₃.THF complex was passed over a anion exchange resin, for example, an anion exchange resin that contains crosslinked polystyrene matrix with tertiary amine and quaternary ammonium functional groups (e.g. Lewatit® MP-64).

In other embodiments, the BF₃ may be provided as, for example, BF₃.pyridine, BF₃.Et₃N, BF₃.MeOH, BF₃.EtOH, BF₃.Et₂O and BF₃.THF, among others. The ¹⁸F-fluoride may be prepared by known methods in the art, for example, by irradiation of ¹⁸O-water. Suitable methods of irradiating ¹⁸O-water are known in the art, and include, using 50-70 uA (e.g. 65 uA) for about 10-30 (e.g. 15) minutes in cyclotron.

In some embodiments, the ¹⁸F-fluoride used has radioactivities of about 10 to about 50 MBq. In some embodiments, the ¹⁸F-fluoride used has radioactivities of about 15 to about 37 MBq.

The disclosed methods provide purified ¹⁸F-TFB with of specific activity of at least 5 GBq/μmol. In some instances, the methods provide ¹⁸F-TFB with a specific activity of at least 8 GBq/μmol. In one embodiment, the purified ¹⁸F-TFB has a specific activity of at least 8.8

GBq/μmol.

The disclosed methods synthesize ¹⁸F-TFB with a radiochemical yield of at least 15% with greater than about 95% purity. In some embodiments, methods provide ¹⁸F-TFB with a radiochemical yield of up to 40% with greater than about 95% purity. In some instances, the radiochemical yield is at least about 10%, at least about 20%, at least about 30%, at least about 40%.

The disclosure provides ¹⁸F-TFB made by the methods provided. The ¹⁸F-TFB is at least about 95% pure, in some embodiments, at least 98% pure. In some embodiments, the methods synthesize ¹⁸F-TFB with at least about 95% purity. In some embodiments, the methods synthesize ¹⁸F-TFB with about 98% purity. The ¹⁸F-TFB provide has a specific activity of at least 3 GBq/μmol, alternatively at least 5 GBq/μmol, alternatively at least 8 GBq/μmol.

In some embodiments, a method of radiolabeling tetrafluoroborate with ¹⁸F-fluoride consists essentially of: (a) trapping ¹⁸F-fluoride on an anion exchange column; (b) reacting ¹⁸F-fluoride with BF₃; and (c) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃ from the anion exchange column, wherein the resultant ¹⁸F-TFB has a specific activity of at least 5 GBq/μmol. In this method, the ¹⁸F-TFB remains attached to the column or cartridge until eluted using an isotonic saline solution. The column or cartridge containing ¹⁸F-TFB may be washed with at least one wash solution before eluting the ¹⁸F-TFB. The method may further include purifying the ¹⁸F-TFB by running over a column or cartridge comprising alumina with a neutral surface chemistry. Suitable columns or cartridges include, but are not limited to, for example, alumina-N SepPak® Plus cartridge (SepPak®). In some embodiments, the eluted ¹⁸F-TFB is passage through a sterilizing filter.

This disclosure provides methods of synthesizing ¹⁸F-TFB in less than 30 minutes, alternatively less than 20 minutes, alternatively less than 10 minutes. In one embodiment, the method of synthesizing ¹⁸F-TFB is performed in about 10 minutes, in some instances in about 9 to 15 minutes. The following Examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and the following examples and fall within the scope of the appended claims.

EXAMPLES Example 1 Synthesis of ¹⁸F-Tetrafluoroborate (¹⁸F-TFB) via Radiofluorination of Boron Trifluoride and Evaluation in Murine C6-Glioma Tumor Model Materials and Methods

Lewatit® MP-64 chloride form resin was procured from Sigma Aldrich (St. Louis, Mo.) and preconditioned with 1 M K₂CO₃ solution (10 equivalent), water (100 equivalent, w/w) and tetrahydrofuran (THF) (100 equivalent, w/w) in a column, and then dried under nitrogen overnight. Acetone, THF and a BF₃ gas cylinder were purchased from Sigma Aldrich. Petroleum ether was procured from Fisher Scientific. Sep-Pak Accell Plus QMA Carbonate Plus Light (46 mg sorbent per cartridge, 40 μm particle size), Alumina-N SepPak Plus cartridges and Alumina-N SepPak Light cartridges were obtained from Waters Corporation (Waltham, Mass.). A Mini-scan radio-TLC scanner from Bioscan, Inc was used to monitor the radiochemical purity. Anion chromatography HPLC (Dionex IC-2100, AS19 analytical column 4.7×150 mm, eluent 35 mM KOH, sample volume 25 uL, flow rate 1 mL/min) was calibrated to measure ¹⁹F-TFB and ¹⁸F-TFB concentrations with conductivity and radioactivity detectors in series. The method was validated by separation of a series of anions (F⁻, Cl⁻, Br⁻, I⁻, NO₃ ⁻, CO₃ ²⁻, and BF₄ ⁻) and OH⁻was negated by the system. Residual organic solvents were analyzed by GC (helium carrier gas flow at 10 cc/min through a MXTWAX column (Restek, Bellefonte, Pa., 0.53 mm ID, 30 m length)). The temperature program was 4 min at 35° C., followed by a temperature ramp of 4° C. per min to a maximum of 150° C.

Preparation of BF₃.THF Complex Solution

A solution of BF3.THF complex in petroleum ether was prepared freshly within 30 min of the radiosynthesis of ¹⁸F-TFB (FIG. 1A). The luer opening of a 20 mL polypropylene syringe was melted closed. A silicone stopper was placed in the opposite opening. A 20 mL sterile vial with PEEK tubing was connected to the 20 mL syringe as shown in FIG. 1 . The syringe body was completely filled with petroleum ether and about half of the sterile vial was also filled with petroleum ether (PE). BF₃ gas (˜5 mL) was flowed into the syringe from a BF3 cylinder through a PEEK tube, thereby displacing the corresponding petroleum ether to the sterile vial. After removal of the BF₃ addition tube, 0.5 mL THF was injected through the silicone stopper. The BF₃ gas was dissolved in the added THF quickly, and petroleum ether was sucked back into the syringe from the auxiliary vial without entry of atmospheric air. The tube was removed and the mixture became a homogenous solution with gentle shaking. The concentration of the BF₃ in the solution was ˜1.8 μmol/mL. (FIG. 1A) FIG. 1B shows an alternative method using a simple manifold/syringe system. As shown in FIG. 1B, Step 1 you fill the syringe A with 5 ml BF₃ and Syringe B with PE/THF mixture; step 2 you switch the valve to the right and step 3 you push PE/THF mixture from Syringe B to the syringe A. Preparation of in-house-made Lewatit® MP-64 cartridge

A 1 mL syringe body was filled with 300 mg Lewatit® MP-64 (carbonate form) and stoppered with some degreasing cotton at both sides. The syringe was cut off and jointed with another 1 mL syringe body using a sheath of silicone tubing (FIG. 2 ).

[¹⁸F]TFB Synthesis Method

An automated synthesis of ¹⁸F-TFB was developed for the preparation of ¹⁸F-TFB (FIG. 3 ). ¹⁸F-fluoride (37.6-40.5 GBq) was made by irradiation of 2.5 mL [¹⁸O]water with 65 uA for 15 min in GE PETtrace cyclotron, and then delivered to the hot cell and trapped on a QMA (46 mg, carbonate form) cartridge. ¹⁸O-enriched water was collected using valve V13. The QMA cartridge was rinsed with 10 mL anhydrous acetone, and flushed with nitrogen for 100 seconds. The freshly prepared BF₄.THF complex solution (5 mL) was filtered by an in-house-made Lewatit® MP-64 cartridge (200-400 mg), and then passed through the QMA cartridge within 10 s to react with the trapped ¹⁸F-fluoride to form ¹⁸F-TFB. The QMA cartridge was rinsed with a solution of 10 mL THF, flushed for 100 s with nitrogen, and rinsed with 13 mL water to further remove impurities. The QMA was then treated with 5 mL sterile 0.9% NaCl, USP solution (saline) to elute into a product vial pre-loaded with an additional 5 mL saline.

The crude ¹⁸F-TFB product solution was further purified from unreacted ¹⁸F-fluoride by passing three alumina-N SepPak Light cartridges before passage through a 0.2 μM sterilizing filter with final collection of the ¹⁸F-TFB in a product vial. (FIG. 3 )

Quality Control

The product ¹⁸F-TFB was analyzed for radiochemical purity by both radio-TLC

(MeOH, Rf =0.8-0.85) and anion chromatography HPLC with radioactivity detector (Dionex IC-2100, AS19 analytical column: 4.7×150 mm; eluent: 35 mM KOH; sample volume: 25 .L; flow rate: 1 mL/min; retention times: 7.6 min for ¹⁸F-TFB, 7.8 min for ¹⁸F-TFB). Chemical purity and specific activity were analyzed by anion chromatography HPLC (retention times: 3.5 min for fluoride, 4.3 min for chloride, and 7.6 min for BF4−). Residual organic solvents were analyzed by GC (helium carrier gas flow at 10 cc/min through a MXTWAX column (Restek, Bellefonte, Pa., 0.53 mm ID, 30 m length)).

In Vivo Imaging

Studies with mice were performed under approval of the Mayo Clinic Institutional Animal Care and Use Committee. Dynamic PET imaging was performed in hNIS-expressing C6 glioma xenografted athymic mice following retro-orbital injection ˜1.1 MBq Na ¹⁸F-TFB at different specific activities (10-0.001 mg TFB/Kg mouse) to assess hNIS activity with ¹⁸F-TFB. In this xenograft model, one flank has hNIS-negative C6 glioma tumor xenograft and the other flank had hNIS-expressing C6 glioma xenograft.

PET scans were acquired for 60 min followed by an X-ray scan using the GENISYS4 PET imaging system (Sofie Biosciences, CA). The images from 40 hNIS-expressing C6 glioma xenografted mice were analyzed for Standardized Uptake Value (SUV) in tumor, stomach, and thyroid using AMIDE image processing software (20). The SUV in tumor was normalized with SUV in stomach to account for difference in ¹⁸F-TFB bioavailability in different animals due to competing uptake in normal organs like thyroid, salivary glands and stomach. Immunohistochemistry

Tumors from 5 age-matched hNIS-expressing C6 glioma xenografted mice were harvested and formalin-fixed. The tumors were then equilibrated in 15% and 30% sucrose with phosphate buffer for 4 days, and frozen for cryo-sectioning. A series of adjacent sections were cut on a cryostat. Each section was 10 μm thick, and mounted onto charged slides (Superfrost Plus slides, Fisherbrand). After drying, the sections were blocked with 10% goat serum for 4 h at room temperature, followed by overnight incubation with 1:4000 dilution of rabbit Anti-human NIS antibody SJ1 (Imanis Life Sciences, Rochester, Minn.) in PBS with 10% goat serum at 4° C. The non-specific anti-human NIS antibody SJ1 in sections was 3× washed in PBS-Tween 20 (0.05%) for 15 min each at room temperature. The sections were incubated with secondary antibody, Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody (Life Technologies, CA) at a dilution of 1:4000 in PBS for 45 min at room temperature. The non-specific secondary antibody was thrice washed in PBS-Tween 20 (0.05%) for 15 min each at room temperature. Following washing, the sections were counter-stained with nuclear DAPI stain. The sections were then cover-slipped with mounting medium and imaged using a Nikon Eclipse Ti inverted microscope at 10× magnification.

Data Analysis and Statistics

Data is expressed as mean±SD. MicroSoft Excel Solver was used to regress the tumor/stomach ratios of ¹⁸F-TFB uptake using a nonlinear least-squares regression algorithm.

Results Radiosynthesis and Quality Control of ¹⁸F-TFB

After irradiation, ¹⁸F-fluoride in ¹⁸O-enriched water was delivered to the hot cell and quantitatively trapped on the QMA cartridge. The QMA cartridge was rinsed with acetone (10 mL) and flushed with nitrogen for 100 s. The freshly prepared BF₃.THF complex solution (5 mL) was passed through an inhouse-made Lewatit® MP-64 cartridge and the QMA cartridge as a single bulk passage of solvent lasting ˜10 s. ¹⁸F-TFB largely remained on the cartridge while 20-40% of the ¹⁸F-fluoride was released from the QMA cartridge, possibly by formation of ¹⁸F-HF under the acidic conditions caused by BF₃. The QMA cartridge was rinsed with a solution of 10 mL THF and 13 mL water to remove the impurities from the QMA cartridge. To decrease the residual acetone and THF in the final product, 100 s of nitrogen flush was applied after THF rinsing. ¹⁸F-TFB was eluted from the QMA cartridge with 5 mL sterile saline to the product vial, in which 5 mL sterile saline was added in advance for further dilution of the product. The crude product solution was purified by trapping the unreacted ¹⁸F-fluoride on three alumina-N SepPak Light cartridges. Using two alumina-N SepPak Light cartridges, the radiochemical purities were 93-96%. Radiochemical purity was increased to >98% by use of an additional alumina-N SepPak Light cartridge. The amount of starting BF₃ for the reaction was found to be critical to determine the radiochemical yields and specific activities. Firstly, 5 mL BF₃.THF/PE solution (˜45 μmol) was used in the reaction and 8.33-0.65 μmol unlabeled TFB with 35.0±3.6% yields were obtained. To decrease the amount of BF₃ for the reaction, the BF₃.THF/PE solution was passed through Lewatit® MP-64 resin immediately before passage through the QMA cartridge. Lewatit® MP-64 is an anion exchange resin, which contains crosslinked polystyrene matrix with tertiary amine and quaternary ammonium functional groups. Separate analysis of the post-Lewatit® MP-64 filtrate showed that 70%, 80% and 90% of the BF₃ in the original 5 mL BF₃.THF/PE solution was retained on 200, 300 and 400 mg Lewatit® MP-64 resin, respectively. Thus, the influence of the Lewatit® MP-64 was not only to retain unlabeled TFB, but also to reduce the amount of BF₃ reactant. Evidently, the BF₃ tertiary amine complex formed on the Lewatit® MP-64 was stronger than the BF₃.THF complex in the solution, which result in retention of BF₃ on the resin.

Investigations with 200 to 400 mg Lewatit® MP-64 resin (Table 1) resulted in the production of unlabeled TFB and product ¹⁸F-TFB in proportional amounts (FIG. 4 ). More Lewatit® MP-64 resin gave less BF₃ in the reaction, resulting in lower radiochemical yield with proportionately less unlabeled TFB (Table 1). Thus, the specific activity of the ¹⁸F-TFB product improved as the amount of Lewatit® MP-64 resin is increased, however, at the cost of decreased radiochemical yield.

TABLE 1 Dependence of overall radiochemical yield and specific activity (N = 3) of ¹⁸F-TFB product on the amount of Lewatit ™ MP-64 resin. Reactions were performed with starting ¹⁸F-fluoride radioactivities of 15-37 MBq. Lewatit ™ MP-64 Unlabeled Uncorrected radiochemical resin (mg) BF₄ ⁻ (μmol) yield (%) 0 8.33 ± 0.65 35.0 ± 3.6 200 2.43 ± 0.12 30.7 ± 2.1 250 1.97 ± 0.15 27.3 ± 1.2 300 1.13 ± 0.15 22.3 ± 2.1 350 0.55 ± 0.05 16.0 ± 1.7 400 0.23 ± 0.06 11.7 ± 1.5

A 300 mg Lewatit® MP-64 resin was used for a high radioactivity level synthesis (40-44 GBq) as a compromise between radiochemical yield and specific activity. The radiochemical yield of ¹⁸F-TFB was 20.0±0.7% (n=3) uncorrected in a synthesis time of 10 min. Radiochemical purity was >98% as shown on silica gel TLC (FIG. 5 ) and anion chromatography HPLC (FIG. 6 ). Specific activities of 8.84±0.56 GBq/μmol (n=3) were achieved from starting ¹⁸F-fluoride activities of 40-44 GBq. In the HPLC analysis of the final product, a carbonate peak at 3.6 min and an unknown impurity peak at 3.8 min were initially observed. Investigation revealed these to be contaminants present on the stock QMA and alumina cartridges. By pretreating the cartridges with 20 mL 0.9% saline and 20 mL water, the peaks were reduced to a trace amount.

Residual acetone and THF were obtained in concentrations of 63-135 ppm and 24-27 ppm, respectively, which were well under the allowed solvent concentration limits (acetone 5000 ppm, THF 720 ppm) set by the International Conference on Harmonization (ICH) for technical requirements for registration of pharmaceuticals for human use (FIG. 7 ).

Stability of ¹⁸F-TFB

After the synthesis, a sample was diluted with water for the analysis. With the eluent of methanol on silica gel plate, purities of >98% were obtained on the radio-TLC scanner. After 20 h, radio-TLC gave a >96% radiochemical purity and HPLC analysis of the product sample showed the ¹⁸F-TFB peak was chemically stable. A slow hydration of ¹⁸F-TFB in water may resulted in the slow decrement of the radiochemical purity. HPLC analysis of a NaBF₄ stock solution (stored for 7 month at room temperature) showed 50% of TFB was decayed and gave a peak of fluoride at 3.4 min.

In Vivo Imaging Studies

Robust uptake of ¹⁸F-TFB was observed in thyroid, stomach, bladder and hNIS-expressing tumors of the C6-glioma xenograft mouse model (FIGS. 9 and 10 ). No uptake of ¹⁸F-TFB was observed in hNIS-negative tumors, confirming specificity of uptake of ¹⁸F-TFB to hNIS-expressing tumors. ¹⁸F-TFB uptake in thyroid and hNIS-expressing tumor showed a bi-phasic kinetic: rapid uptake over the first 10 min was followed by slower uptake until 30 min with little subsequent change. The stomach showed linear increase in ¹⁸F-TFB uptake over 60 min. Stomach uptake was independent of specific activity of ¹⁸F-TFB while uptake in hNIS-expressing tumor and thyroid was dependent on specific activity of ¹⁸F-TFB. The uptake of ¹⁸F-TFB by hNIS-expressing tumor was higher at high specific activity (>13 MBq/μmol) as compared to lower specific activity (3 MBq/μmol). This trend was also seen for thyroid.

For a more detailed analysis of the effect of specific activity of ¹⁸F-TFB on uptake in hNIS-expressing tumors, a 60 min time-point was chosen and a range of specific activities (10-0.001 mg TFB injected/kg mouse weight) was tested. The uptake in tumor was normalized to stomach uptake to account for differences in bioavailability of ¹⁸F-TFB across animals. The uptake of ¹⁸F-TFB in hNIS-expressing C6 tumor showed dependence on specific activity at 10-0.5 mg TFB/Kg mouse weight or 0-10 MBq/μmol considering ˜1.1 MBq radioactivity injected in a ˜25 g mice. But this trend was not observed for higher specific activities (>10 MBq/μmol TFB or <0.5 mg TFB/Kg mouse weight) (FIG. 11 ). At these higher specific activities the uptake of ¹⁸F-TFB was no longer dependent on specific activity but exhibited high variability. Immunohistochemistry analysis for hNIS in tumor sections from 5 mice showed significant intra-tumoral and inter-tumoral variability of expression of hNIS (FIG. 12 ) that may play a role in the variability of ¹⁸F-TFB uptake observed in tumors.

Discussion

BF₃ is a versatile Lewis acid and widely used in the chemistry. It is known that BF₃ will form TFB in the presence of water via a fluoride exchange reaction, which was well documented [Ref. 17, 18]. Therefore, the present disclosure aimed to synthesize high specific activity ¹⁸F-TFB with the reaction of BF₃ and ¹⁸F-fluoride. The ¹⁸F-fluoride was conveniently trapped on a QMA cartridge and the reaction was found to proceed by addition of a BF₃ complex in solution. A variety of BF₃ complexes (e.g. BF₃.pyridine, BF₃.Et₃N, BF₃.MeOH, BF₃.EtOH, BF₃.Et₂O and BF₃.THF) were tested in the reaction. With respect to yield and specific activity, BF₃.THF complex gave the best results. Therefore, BF₃.THF complex was used for the further optimization. In initial exploration, only 5-10% radiochemical yields of ¹⁸F-TFB were obtained with commercially available BF₃.THF solutions. To improve radiochemical yields of ¹⁸F-TFB, a BF₃.THF/PE solution was freshly prepared with BF₃ gas in a simple apparatus described above (FIG. 1A or 1B). To improve specific activity, the freshly prepared BF₃.THF/PE solution was passed through Lewatit® MP-64 resin immediately before passage through the QMA cartridge. As shown in Table 1, depending on the amount of Lewatit® MP-64 resin used in the process, a trade-off was found to exist between radiochemical yield and specific activity of the ¹⁸F-TFB product.

Using 300 mg Lewatit® MP-64 resin was selected for a high radioactivity level synthesis (40-44 GBq) as a compromise between radiochemical yield and specific activity. Three runs in this condition achieved specific activities of 8.84±0.56 GBq/.mol and uncorrected radiochemical yields of 20.0±0.7%. In some embodiments, to optimize specific activity at the sacrifice of radiochemical yield, the use of 400 mg Lewatit® MP-64 resin and 80 GBq starting activity would result in ¹⁸F-TFB specific activity of approximately 30 GBq/μmol with an overall uncorrected radiochemical yield near about 12%. The high specific activities obtained by our method are unlikely to be obtained with the previously reported isotope exchange method [Ref 14].

The methods provided improve upon the isotope exchange method by providing significantly enhanced radiochemical yields (˜31% with use of 200 mg Lewatit® MP-64 resin versus ˜10% for isotopic exchange [Ref. 14]) at moderate specific activity (˜5 GBq/μmol (estimated) versus ˜1 GBq/μmol [Ref. 14]). A putative chemical reaction mechanism for synthesis of ¹⁸F-TFB via BF₃ is shown in scheme 1. BF₃ hydrates with water quickly to form HBF₃OH [Ref 17]. Although the BF₃. THF complex solution is prepared in near anhydrous conditions, the QMA cartridge is likely containing trace amounts of water after trapping of the ¹⁸F-fluoride and treatment with acetone and nitrogen. Indeed, the ¹⁸F-fluoride itself may be in a hydrated form [Ref. 19] on the QMA cartridge. Although it is possible that BF₃ reacts directly with ¹⁸F-fluoride ion, not to be bound by any theory, it is believed that HBF₃OH is the more likely intermediate to react with ¹⁸F-fluoride to make ¹⁸F-TFB. In the presence of water, HBF₃OH may react further to form a series of intermediates, which ends with the release of boric acid and HF [Ref. 17]. The release of ¹⁹F-fluoride from BF₃ may represent a source of unlabeled fluoride that can decrease the specific activity of the product. (Scheme 1)

Jauregui-Osoro et al. (14) estimated that the administration of ˜400 MBq ¹⁸F-TFB synthesized by the conventional method to a human subject would result in a plasma concentration of ˜0.1 μM TFB. Considering the IC₅₀ of TFB to be 0.1-1 μM for inhibition of iodine uptake by NIS in thyroid (21), it is desirable to increase ¹⁸F-TFB specific activity above ˜5 GBq/μmol to avoid a pharmacological effect (14). The presently reported synthesis method for ¹⁸F-TFB achieves this goal. At a specific activity of 8 GBq/μmol, a ˜400 MBq administered dose of ¹⁸F-TFB would give an estimated in vivo concentration of ˜0.02 μM TFB which should not exhibit a pharmacologic effect.

To evaluate the influence of ¹⁸F-TFB specific activity on in vivo uptake by NIS-expressing tissues, we employed a hNIS-expressing C6 tumor xenograft mouse model. As expected, ¹⁸F-TFB was taken up by selected organs expressing NIS in the xenograft mouse model. Among the select organs, thyroid and hNIS-expressing tumor were sensitive to specific activity of ¹⁸F-TFB as ¹⁸F-TFB was being transported using NIS in these organs. On the other hand, in stomach, which also possesses NIS (22-24), the uptake of ¹⁸F-TFB was found to be independent of its specific activity. The insensitivity of ¹⁸F-TFB uptake to specific activity in stomach was not clarified, but may point to different kinetic properties of the NIS protein in gastric mucosal cells as compared to thyroid and hNIS-expressing tumor (23, 24). Another possible explanation is that ¹⁸F-TFB entering the gastric epithelial cells is immediately effluxed into the stomach lumen such that the intracellular concentration (e.g. in gastric parietal cells) is never in equilibrium with the interstitial fluid so unidirectional transport continues unabated. A biphasic response was observed in hNIS-expressing tumor uptake of ¹⁸F-TFB versus administered dose of unlabeled TFB. The ¹⁸F-TFB uptake in tumor decreased with increasing amount of administered TFB over the range of 0.5-10 mg TFB/kg mouse weight, but this trend was not observed for higher specific activities (<0.5 mg TFB/kg mouse weight). Rather, the tumor uptake was constant but highly variable for administered TFB doses <0.5 mg/kg. The reason for this trend is not clear but it is possible that at high specific activity, factors other than specific activity contribute to the variability, such as variability in the inter- and intra-tumoral expression and/or activity of hNIS, number of tumor cells expressing hNIS, heterogeneity of tumor perfusion and/or oxygenation, variability of tumor size or the indirect influence of differences in the physiological distribution of radiotracer to other areas of the body. The large variation seen in hNIS expression levels in the C6 glioma xenografts may reflect the fact that the C6-hNIS transduced cell line was not a clonal population but included high, low and negative expressing cells. The ability of the ¹⁸F-TFB-PET method to reliably report on viral infection depends on hNIS expression within infected cells and possibly post-translational events that influence hNIS transporter activity (25). These considerations must also be kept in mind for future studies in monitoring hNIS transduction in human studies that may also entail significant heterogeneity of hNIS expression following viral therapies. Nonetheless, it was encouraging to observe a broad range of specific activities of ¹⁸F-TFB over which tumor uptake was robust.

Conclusion

A solid-phase supported synthesis of ¹⁸F-TFB was developed via radiofluorination of BF₃. With the optimized condition, the radiochemical yield of¹⁸F-TFB was 20.0±0.7% (n=3) uncorrected in a synthesis time of 10 min. Specific activities of 8.84±0.56 GBq/μmol (n=3) were achieved with starting ¹⁸F-fluoride radioactivities of 40-44 GBq. This method offers a convenient synthesis of high specific activity ¹⁸F-TFB. A positive correlation was observed between specific activity of ¹⁸F-TFB and hNIS-expressing C6 glioma xenografts for lower specific activities resulting in administration of TFB exceeding 0.5 mg/kg in mice. The increased specific activity of ¹⁸F-TFB may allow for enhanced PET imaging of hNIS reporter in future human studies.

REFERENCES FOR EXAMPLE 1

[1] Chung J K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43:1188-200.

[2] Penheiter A R, Russell S J, and Carlson S K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 2012; 12:33-47.

[3] Ahn B-C. Sodium Iodide Symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2012; 2:392-402.

[4] Daniels G H and Haber D A. Will radioiodine be useful in treatment of breast cancer? Nat Med 2000; 6:859-60.

[5] Dai G, Levy O, and Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379:458-60.

[6] Eskandari S, Loo D D F, Dai G, Levy O, Wright E, and Carrasco N. Thyroid Na+/I. Symporter: mechanism, stoichiometry, and specificity. J. Biol. Chem 1997; 272:27230-8.

[7] Sparagana M, Little A, and Kaplan E. Rapid evaluation of thyroid nodules using 99mTc-Pertechnetate scanning. J Nucl Med 1970; 11:224-5.

[8] Ryo U Y, Vaidya P V, Schneider A B, Bekerman C, and Pinsky S M. Thyroid imaging agents: a comparison of 1-123 and Tc-99m pertechnetate. Radiology 1983; 148:819-22.

[9] Groot-Wassink T, Aboagye E O, Wang Y, Lemoine N R, Reader A J, and Vassaux G. Quantitative imaging of Na/I Symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9:436-42.

[10] Schmitz J. The production of [1241]iodine and [86Y]yttrium. Eur. J. Nucl. Med. Mol. Imag 2011; 38:4-9.

[11] Anbar M, Guttmann S, and Lewitus Z. The Accumulation of Fluoroborate Ions in Thyroid Glands of RatS1. Endocrinology 1960; 66:888-90.

[12] Anbar M, Guttmann S, and Lewitus Z. Effect of Monofluorosulphonate, Difluorophosphate and Fluoroborate Ions on the Iodine Uptake of the Thyroid Gland. Nature 1959; 183:1517-8.

[13] Anbar M and Guttmann S. The Isotopic Exchange of Fluoroboric Acid with Hydrofuoride Acid. J. Phys. Chem 1960; 64:1896-9.

[14] Jauregui-Osoro M, Sunassee K, Weeks A J, Berry D J, Paul R L, Cleij M, et al. Synthesis and biological evaluation of F-18 tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur. J. Nucl. Med. Mol. Imag 2010; 37:2108-16.

[15] Weeks A J, Jauregui-Osoro M, Cleij M, Blower J E, Ballinger J R, and Blower P J. Evaluation of [¹⁸F tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nuclear Medicine Communications 2011; 32:98-105.

[16] Youn H, Jeong J M, and Chung J-K. A new PET probe, F-18-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur. J. Nucl. Med. Mol. Imag. 2010; 37:2105-7.

[17] Wamser C A. Equilibria in the System Boron Trifluoride-Water at 25 <C. J. Am. Chem. Soc 1951; 73:409-16.

[18] Wamser C A. Hydrolysis of Fluoboric Acid in Aqueous Solution. J. Am. Chem. Soc 1948; 70:1209-15.

[19] Cai L, Lu S, and Pike V W. Chemistry with F-18 fluoride ion. Eur. J. Org. Chem 2008:2853 73.

[20]. Loening A M, Gambhir S S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2:131-137.

[21]. Lecat-Guillet N, Ambroise Y. Discovery of aryltrifluoroborates as potent sodium/iodide symporter (NIS) inhibitors. ChemMedChem. 2008; 3:1207-1209.

[22]. Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I− symporter (NIS): mechanism and medical impact. Endocr Rev. 2014; 35:106-149.

[23.] Wolosin J M. Ion transport studies with H+−K+−ATPase-rich vesicles: implications for HC1 secretion and parietal cell physiology. Am J Physiol. 1985; 248:G595-607.

[24]. R. McG. Harden, W. D. Alexander, J. Shimmins, D. Chisholm. A comparison between the gastric and salivary concentration of iodide, pertechnetate, and bromide in man. Gut. 1969; 10:928-930.

[25 ]. Kogai T1, Brent G A. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135:35

The citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

EXAMPLE 2 Biodistribution and Radiation Dosimetry of ¹⁸F-Tetrafluoroborate (¹⁸F-TFB) in Healthy Human Subjects

¹⁸F-tetrafluoroborate (¹⁸F-TFB) has been identified as a promising iodide analog for imaging of thyroid cancer and monitoring of NIS expression as a reporter probe in viral therapy applications. This Example demonstrates the pharmacokinetics, biodistribution and radiation dosimetry of high-specific activity ¹⁸F-TFB in healthy human subjects. Methods: ¹⁸F-TFB was synthesized via ¹⁸F-fluorination of BF₃ with specific activity of 2.2±0.9 GBq/μmol. Dynamic PET/CT imaging over 4 hours was performed after intravenous administration of ¹⁸F-TFB (333-407 MBq) in 4 female and 4 male healthy volunteers (35±10 year old). Initial scanning over the heart allowed definition of the blood pharmacokinetics, while whole body scans at 2 and 3.5 hours provided data for biodistribution and radiation dosimetry. Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to determine the safety of ¹⁸F-TFB administration. Results: ¹⁸F-TFB administration was well tolerated with no significant findings on vital signs or clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of radioactivity with the two rapid clearance phases over the first 30-45 min, followed by a slower clearance phase. HPLC analysis showed insignificant ¹⁸F-labeled metabolites in the blood and urine over the length of the study (4 hours). At 2 hours p.i., high uptakes were seen in thyroid, stomach, salivary glands, and kidney. Urinary clearance of ¹⁸F-TFB was prominent. Minor changes were seen in ¹⁸F-TFB biodistribution from 2-4 hours p.i. A low level of metabolic defluorination was evidenced by low accumulation of ¹⁸F-radioactivity in bone (SUV=1.4±0.5 in males, SUV=1.3±0.9 in females at 3.5 hours). Conclusion: This initial study in healthy human subjects showed ¹⁸F-TFB to be safe, metabolically stable, and distribute in the human body similar to other iodide analogs with prominent physiologic distribution to thyroid, stomach, salivary glands and bladder, with thyroid as the dose-critical organ. ¹⁸F-TFB can be used as a hNIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

Example 1 demonstrates high specific radioactivity syntheses of ¹⁸F-TFB via the reaction of boron trifluoride (BF₃) and ¹⁸F-fluoride. We demonstrated the relationship of ¹⁸F-TFB specific radioactivity and PET-delineated radiotracer uptake in NIS-transfected C6-glioma xenograft bearing mice, confirming the desirability of high specific radioactivity to avoid saturation effects at the NIS transporter. In this study, we report PET/CT imaging data with ¹⁸F-TFB in healthy male and female participants to describe physiologic distribution of the radiotracer and allow calculation of radiation dosimetry estimates.

Materials and Methods Radiotracer Synthesis

¹⁸F-TFB was prepared and formulated in sterile 0.9% NaCl under cGMP conditions as previously described (12). Decay-corrected radiochemical yields of 32±2% and radiochemical purities (RCPs) >98% were obtained. Specific radioactivity of 2.2±0.9 GBq/μmol was achieved from starting ¹⁸F-fluoride radioactivity of 20-31 GBq. In vitro RCP remained >96% up to 8 hours at room temperature.

Human Participants

Approval of the study was obtained from the Mayo Clinic Institutional Review Board and all participants provided informed consent. Four male (36±14 y) and four female (35±8 y) healthy volunteers were enrolled in the study. Participants were excluded that had previous diagnosis of cancer or clinically significant cardiovascular, renal, pulmonary, metabolic, and endocrine (thyroid) diseases. Participants were not required to fast prior to the imaging study but instructed to remain well-hydrated.

PET/CT Imaging Protocol

The imaging protocol is illustrated in FIG. 13 . After voiding of the bladder, participants were positioned in a GE 690XT PET/CT scanner (GE HealthCare, Waukesha, Wis.) in a supine position with the heart in the center of the axial field of view. Intravenous catheters were placed in both arms for radiotracer injection and blood sampling. Computed tomography scans of the thorax were initially acquired in the preparation for a dynamic PET data acquisition over the heart for the first 45 min following commencement of radiotracer administration. ¹⁸F-TFB (333-407 MBq) was administered over 1 minute into one of the catheters. The frame sequence for initial dynamic PET acquisition was 15×4, 8×15, 4×30, and 8×300 seconds. Following the dynamic heart scan, the participants were allowed a break from the scanner, during which time voided their bladders. Two additional PET/CT scans, from the vertex of the skull to mid-thigh, were performed at 2 hours and 3.5 hours respectively. The last PET/CT scan was completed ˜4 hours post-injection.

Measurements in Venous Blood and Urine Samples

Urine was collected after each PET/CT scan (approximately 55, 160, 250 min), and venous blood samples were collected at 40, 145 and 235 min, post-injection, as shown in FIG. 13 . Blood samples (3-4 mL) were collected in heparinized tubes and placed on ice. The blood samples were centrifuged at 3000 g for 5 min to obtain plasma. Urine was measured for urine volume and radioactivity concentration as measured in a calibrated gamma counter. Analysis for metabolites in plasma and urine was performed by ion-chromatography HPLC, allowing estimation of the fraction of radioactivity as nonmetabolized ¹⁸F-TFB.

Safety Measurements for ¹⁸F-TFB Administration

Vital signs (heart rate, systolic and diastolic blood pressures, respiratory rate, and temperature) were measured prior to ¹⁸F-TFB administration and at 45 and 240 min post-injection. Venous blood samples were taken prior to ¹⁸F-TFB administration and at ˜240 min post-injection for a panel of clinical laboratory tests to evaluate the safety of the radiotracer administration.

PET/CT Image Analysis

All PET scans images were reconstructed using 3D OSEM and time-of-flight reconstruction. Volumes of interest (VOI's) of organs were drawn using PMOD software (Ver. 3.5). Standardized Uptake Values (SUVs) normalized to body weight were then calculated for each VOI. Time-activity curves (TACs) were evaluated from the initial dynamic scan over the heart for left-ventricular blood pool, lung and liver regions.

Radiation Dosimetry Estimation

Radiation dosimetry estimates were calculated from organ residence times using OLINDA software (Ver. 1.1), assuming a bladder voiding interval of 3.5 hours. Gender-specific organ masses for the conversion of SUV to disintegrations per organ per unit radioactivity administered (Bq-hr/Bq) were taken from Schlein et al. (15).

Statistics

Data are expressed as mean±SD. Statistical significance of differences in SUV values between PET/CT scans were determined by ANOVA.

Results Pharmacokinetics of ¹⁸F-TFB

The initial 45-min dynamic PET/CT scan over the heart allowed evaluation of the early kinetics of ¹⁸F-TFB in the left-ventricular blood pool (LVBP) as in indication of the pharmacokinetics of this radiotracer. FIG. 14 shows the time-activity curves in LVBP, lung, and liver in a representative participant. Peak values of radioactivity concentration were seen at ˜1 min for LVBP and lung regions, whereas the peak in liver was at ˜2 min post-administration of ¹⁸F-TFB. Blood clearance was multiphasic, with clearance proceeding to the end of the 4-h measurement period. Continued radiotracer washout was also seen in lung and liver.

Metabolite Analysis

HPLC metabolite analysis of plasma samples at 40 min p.i. showed >97% of radioactivity to be in the form of metabolically intact ¹⁸F-TFB (Table 2). Similarly, all urine samples taken from urine collections at approximately 50, 160, 250 min showed >97% of radioactivity in the form of ¹⁸F-TFB. The accumulated percentage of administered ¹⁸F-TFB in the urine at the end of study (˜250 min) was 40±4% for males and 47±7% for females. Thus, renal clearance of nonmetabolized ¹⁸F-TFB is a major excretion pathway for ¹⁸F-TFB.

TABLE 2 Metabolite analysis of ¹⁸F-TFB in plasma and urine of healthy participants 40 min^(a) 145 min^(a) 235 min^(a) Accumulative Males Females Males Females Males Females Males Females Whole blood (SUV) 3.0 ± 0.2 3.1 ± 0.9  2.1 ± 0.2  1.7 ± 0.4 1.7 ± 0.2 1.4 ± 0.4 — — Plasma (SUV) 3.8 ± 0.2 3.8 ± 1.0  2.8 ± 0.3  2.1 ± 0.5 2.0 ± 0.1 1.7 ± 0.5 — — Urine (% Dose) 15 ± 2^(b ) 16 ± 3  13 ± 3 18 ± 3 10 ± 2^(b ) 12 ± 2  40 ± 4^(b) 47 ± 7 % Intact Plasma 97 ± 2  97 ± 3^(c ) —^(d) —^(d) —^(d) —^(d) — — ¹⁸F-TFB Urine 96 ± 2  98 ± 1  97 ± 2 98 ± 1 98 ± 1  97 ± 2  — — Values are mean ± SEM (n = 4) ^(a)Time-points are shown for blood samples; urine samples were collected ~10 min later. ^(b)No urine in third collection in one of the male subjects. ^(c)One plasma sample was not used because precipitate was observed in the HPLC analysis. ^(d)Metabolite data were not obtained in second and third plasma samples analysis because the low radioactivity levels were below detection limit.

Biodistribution of ¹⁸F-TFB

Representative images from the whole-body PET/CT scan at 2 hours post-injection are shown in FIG. 15 and the biodistribution data are summarized in Table 3. Robust uptake of ¹⁸F-TFB was observed in thyroid, stomach, salivary glands, and kidney. Prominent clearance of tracer through kidney to bladder was also observed. Minor differences were observed in the SUV values between the first (2 hours) and second (3.5 hours) whole body PET/CT scans, showing the tracer distribution to be stable at least after 2 hours. Bone uptake was moderately increased from 2 to 3.5 hours in males, indicating a low level of defluorination of ¹⁸F-TFB, but the increase was not statistically significant in females.

TABLE 3 PET/CT-derived distribution of ¹⁸F-TFB in healthy participants 2 h post-injection (SUV) 3.5 h post-injection (SUV) Organ Males Females Males Females Bone 0.80 ± 0.33 0.74 ± 0.20  1.4 ± 0.5* 1.3 ± 0.9 Brain 0.39 ± 0.14 0.42 ± 0.15 0.74 ± 0.26 0.61 ± 0.34 Breast — 2.8 ± 0.4 — 3.9 ± 1.4 Gallbladder 2.7 ± 1.5 3.7 ± 1.0 4.2 ± 1.7 5.0 ± 1.6 Intestines 2.9 ± 1.0 5.0 ± 2.7 4.4 ± 1.0 6.0 ± 3.1 Kidney 7.0 ± 2.5 5.6 ± 0.7 11 ± 3  6.3 ± 2.4 Liver 2.3 ± 1.0 2.7 ± 0.5 3.6 ± 1.2 3.5 ± 1.6 Lung 1.0 ± 0.4 1.2 ± 0.4 1.7 ± 0.6 1.5 ± 0.8 Muscle 0.71 ± 0.31 0.65 ± 0.35 0.96 ± 0.31 0.78 ± 0.54 Myocardium 3.2 ± 0.9 2.8 ± 0.5 5.0 ± 0.9 3.8 ± 1.8 Pancreas 3.4 ± 0.7 3.1 ± 1.7 6.2 ± 2.1 3.0 ± 1.2 Parotid 11 ± 9  20 ± 11 16 ± 13 25 ± 15 Spleen 4.1 ± 1.2 4.3 ± 1.0 6.3 ± 1.1 5.5 ± 2.8 Stomach 33 ± 15 72 ± 10 70 ± 32 51 ± 18 Thyroid 55 ± 31 50 ± 11  82 ± 42* 58 ± 12 Values are mean ± SEM (n = 4) *p < 0.05 versus 2 h

Radiation Dosimetry Estimates

Table 4 shows organ residence times derived from the biodistribution data. Bladder residence time was estimated by the bladder emptying model within the OLINDA software, assuming a 3.5 hours bladder voiding period. Estimated organ absorbed doses are shown in Table 5. The dose-critical organ is thyroid, with dose estimates of 0.26 and 0.36 mSv/MBq in males and females, respectively. The prominent excretion through the bladder resulted in moderately high doses to the bladder wall, with doses depending on voiding frequency. Effective doses are shown in Table 6. Effective dose was higher in females (0.065 mSv/MBq) relative to males (0.036 mSv/MBq).

TABLE 4 Organ residence times of ¹⁸F-TFB in healthy participants Residence Time Residence Time Organ Males (min) Females (min) Bone 4.6 ± 1.3 3.1 ± 0.3 Brain 1.2 ± 0.4 1.3 ± 0.2 Breast — 2.8 ± 0.9 Gallbladder 0.06 ± 0.03 0.09 ± 0.04 Intestines 5.7 ± 1.9 13 ± 7  Kidney 4.2 ± 1.2 3.9 ± 0.8 Liver 8.3 ± 3.9 10 ± 2  Lung 2.1 ± 0.7 2.4 ± 0.2 Muscle 36 ± 14 26 ± 8  Myocardium 2.1 ± 0.6 1.8 ± 0.3 Pancreas 0.7 ± 0.3 0.58 ± 0.08 Parotid 1.7 ± 1.1 3.3 ± 1.2 Spleen 1.5 ± 0.4 1.6 ± 0.2 Stomach 11 ± 5  24 ± 12 Thyroid 2.0 ± 0.7 2.3 ± 0.9 Bladder 17 ± 2  19 ± 4  Values arc mean ± SEM (n = 4)

TABLE 5 Estimated absorbed radiation dose for ¹⁸F-TFB (mSv/MBq) Dose (mSv/MBq) Organ Males Females Adrenals 0.008 0.012 Brain 0.004 0.005 Breasts 0.002 0.028 Gallbladder Wall 0.012 0.022 Lower Large Intestine Wall 0.009 0.015 Small Intestine Wall 0.027 0.066 Stomach Wall 0.076 0.184 Upper Large Intestine Wall 0.045 0.109 Heart Wall 0.024 0.030 Kidneys 0.049 0.052 Liver 0.021 0.033 Lungs 0.009 0.014 Muscle 0.008 0.011 Ovaries — 0.020 Pancreas 0.034 0.043 Red Marrow 0.005 0.008 Osteogenic Cells 0.008 0.009 Skin 0.003 0.004 Spleen 0.033 0.047 Testes 0.005 — Thymus 0.004 0.005 Thyroid 0.26  0.36 Urinary Bladder Wall 0.14  0.22 Uterus — 0.022 Total Body 0.008 0.011

TABLE 6 Effective dose for ¹⁸F-TFB in healthy participants Males Females Effective Dose (mSv/MBq) 0.036 0.065

¹⁸F-TFB Safety Data

Vital signs (heart rate, diastolic and systolic blood pressures, and respiratory rate) were monitored before ¹⁸F-TFB administration and throughout the PET/CT imaging period. No significant changes in the vital signs were found after ¹⁸F-TFB administration (data not shown). Likewise, a panel of clinical laboratory blood tests was measured to assess for effects of ¹⁸F-TFB administration on blood chemistries, including electrolytes, and liver and kidney functional tests (Supplemental data not shown). No significant changes were observed in the clinical laboratory test values for the samples acquired after ¹⁸F-TFB administration relative to baseline.

Discussion

This Example evaluated the pharmacokinetics, biodistribution and radiation dosimetry of high specific radioactivity ¹⁸F-TFB in eight healthy human participants. The tracer was well-tolerated and no adverse effects were noted. hNIS is known to be highly expressed in certain tissues (thyroid, breast, stomach and salivary glands) as well as hNIS-transfected tissues. Thus, non-invasive PET imaging of hNIS activity could be used to facilitate the treatment of thyroid and breast cancer and gene therapies that employ hNIS as a reporter gene. In principle, the ¹⁸F-TFB PET method may also enable quantitative estimation of hNIS activity in tissues. Therefore, it may be useful to monitor changes over time for understanding the progression of disease and serial assessments of therapy response.

Since only high specific radioactivity ¹⁸F-TFB was administered in this study, we did not explore the effects of specific radioactivity over a broader range. However, in our previous preclinical study with NIS-transfected C6 glioma xenografts in mice we showed that as specific radioactivity was decreased such that TFB administration levels exceeded ˜0.5 mg/kg, there was decreases seen in both thyroid and tumor uptake. Since thyroid uptake levels in the healthy participants in this study were very high, it is inferred that the specific radioactivity levels were sufficient to avoid any saturation effects do to administered TFB mass.

The regional distribution of ¹⁸F-TFB in healthy participants was found to be consistent with known hNIS expression levels throughout the body tissues. The slow accumulation of ¹⁸F-radioactivity seen in SUV values between the 2 and 3.5 hours imaging time points could be evidence of a minor degree of radiotracer defluorination, but since routine ¹⁸F-TFB PET images will likely be acquired in the 1-2 hours post-injection period, the impact of this accumulation is of minor significance. Indeed, bone uptake was not qualitatively remarkable in either the 2 or 3.5 hours images. Overall, the biodistribution data confirm ¹⁸F-TFB to be an excellent iodide analog radiotracer with excellent in vivo stability.

The estimated radiation doses were higher in thyroid, urinary bladder wall, lower large Intestine wall, small intestine wall, upper large intestine wall, heart wall, kidneys, liver, pancreas, and spleen, but on par with other ¹⁸F-labeled radiopharmaceuticals and appropriate for clinical use. Further decrease in bladder wall doses can be realized with good hydration and more frequent voiding of the bladder. Estimated effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females. Our data on the biodistribution and dosimetry estimates for ¹⁸F-TFB are in general agreement with the results very recently published O'Doherty et al. (11) in five patients with thyroid cancer. In that study, 2 male and 3 female subjects were studied and the results from both genders were pooled. The specific radioactivity of their ¹⁸F-TFB preparations (24±13 MBq/μg) was similar to the specific radioactivity obtained in this study.

Conclusion

The pharmacokinetics and biodistribution of high-specific activity ¹⁸F-TFB in healthy human participants support its use as an iodide analog radiotracer for evaluation of thyroid and breast cancers and monitoring of gene therapies that employ the hNIS reporter gene. The radiation dosimetry estimates are on par with other ¹⁸F-labeled radiopharmaceuticals with prominent renal excretion (e.g. ¹⁸F-FDG) and are acceptable for clinical imaging purposes.

REFERENCES FROM EXAMPLE 2

1. Chung J K. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med. 2002; 43:1188-1200.

2. Penheiter A R, Russell S J, and Carlson S K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012; 12:33-47.

3. Ahn B-C. Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back. Theranostics. 2012; 2:392-402.

4. Dai G, Levy O, and Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996; 379:458-460.

5. Eskandari S, Loo DDF, Dai G, Levy O, Wright EM, and Carrasco N. Thyroid Na+/I− Symporter: Mechanism, Stoichiometry, and Specificity. J Biol Chem. 1997; 272:27230-27238.

6. Miller A and Russell S J. The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin on Biol Ther. 2016; 16:15-32.

7. Jauregui-Osoro M, Sunassee K, Weeks A J, Berry D J, Paul R L, Cleij M, et al.

Synthesis and biological evaluation of F-18 tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur Nucl Med Mol Imaging. 2010; 37:2108-2116.

8. Weeks A J, Jauregui-Osoro M, Cleij M, Blower J E, Ballinger J R, and Blower P J. Evaluation of F-18 -tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Comm. 2011; 32:98-105.

9. Marti-Climent J M, Collantes M, Jauregui-Osoro M, Quincoces G, Prieto E, Bilbao I, et al. Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand F-18-tetrafluoroborate. EJNMMI Research. 2015; 5:70.

10. Youn H, Jeong J M, and Chung J-K. A new PET probe, F-18-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur J Nucl Med Mol Imaging. 2010; 37:2105-2107.

11. O'Doherty J, Jauregui-Osoro M, Brothwood T, Szyszko T, Marsden P, O'Doherty M, Cook G, Blower P, Lewington V. ¹⁸F-tetrafluoroborate (¹⁸F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients. J Nucl Med. 2017 pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252. [Epub ahead of print]

12. Jiang H L, Bansal A, Pandey M K, Peng K W, Suksanpaisan L, Russell S J, et al. Synthesis of F-18-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model. J Nucl Med 2016; 57:1454-1459.

13. Khoshnevisan A, Jauregui-Osoro M, Shaw K, Torres J B, Young J D, Ramakrishnan N K, et al. F-18 tetrafluoroborate as a PET tracer for the sodium/iodide symporter: the importance of specific activity. EJNMMI Research. 2016; 6:34.

It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited, and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses are intended to be encompassed by the claims attached hereto. 

1. A method for imaging of thyroid or breast cancer, the method comprising: imaging of thyroid or breast cancer using a high specific activity preparation of ¹⁸F-tetrafluoroborate having at least 95% radiochemical purity.
 2. The method of claim 1 wherein the ¹⁸F-tetrafluoroborate is prepared by direct radiofluorination on boron trifluoride (BF₃) by reacting the BF₃ directly with ¹⁸F-fluoride.
 3. The method of claim 1 wherein the ¹⁸F-tetrafluoroborate is prepared by: (a) reacting ¹⁸F-fluoride with boron trifluoride (BF₃); and (b) isolating the ¹⁸F-tetrafluoroborate from unreacted ¹⁸F-fluoride and BF₃.
 4. The method of claim 3, wherein the BF₃ in step (b) is provided in a solution of boron trifluoride-tetrahydrofuran (BF₃-THF) complex in petroleum ether.
 5. The method of claim 4, wherein BF₃-THF complex is filtered to remove TFB before reacting with ¹⁸F-fluoride.
 6. The method of claim 3, wherein the column is washed after step (b) to remove unreacted BF₃ and residual solvent from the column.
 7. The method of claim 1 wherein the ¹⁸F-tetrafluoroborate (¹⁸F-TFB) is prepared by: (a) trapping ¹⁸F-fluoride on an anion exchange column; (b) reacting ¹⁸F-fluoride with boron trifluoride (BF₃); and (c) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃ from the anion exchange column, wherein the resultant ¹⁸F-TFB has a specific activity of at least 5 GBq/μmol.
 8. The method of claim 1, wherein an effective dose of ¹⁸F-tetrafluoroborate is about 0.036 mSv/MBq in males and about 0.064 mSv/MBq in females.
 9. The method of claim 1, wherein the ¹⁸F-tetrafluoroborate has a specific activity of at least 5 GBq/μmol.
 10. The method of claim 1, wherein the ¹⁸F-tetrafluoroborate has a specific activity of at least 8 GBq/μmol.
 11. A method for imaging of thyroid, breast, stomach, salivary glands or kidney, the method comprising: imaging of thyroid, breast, stomach, salivary glands or kidney using a high specific activity preparation of ¹⁸F-tetrafluoroborate having at least 95% radiochemical purity.
 12. The method of claim 11 wherein the ¹⁸F-tetrafluoroborate is prepared by direct radiofluorination on boron trifluoride (BF₃) by reacting the BF₃ directly with ¹⁸F-fluoride.
 13. The method of claim 11 wherein the ¹⁸F-tetrafluoroborate is prepared by: (a) reacting ¹⁸F-fluoride with boron trifluoride (BF₃); and (b) isolating the ¹⁸F-tetrafluoroborate from unreacted ¹⁸F-fluoride and BF₃.
 14. The method of claim 13, wherein the BF₃ in step (b) is provided in a solution of boron trifluoride-tetrahydrofuran (BF₃-THF) complex in petroleum ether.
 15. The method of claim 14, wherein BF₃-THF complex is filtered to remove TFB before reacting with ¹⁸F-fluoride.
 16. The method of claim 13, wherein the column is washed after step (b) to remove unreacted BF₃ and residual solvent from the column.
 17. The method of claim 11 wherein the ¹⁸F-tetrafluoroborate (¹⁸F-TFB) is prepared by: (a) trapping ¹⁸F-fluoride on an anion exchange column; (b) reacting ¹⁸F-fluoride with boron trifluoride (BF₃); and (c) isolating the ¹⁸F-TFB from unreacted ¹⁸F-fluoride and BF₃ from the anion exchange column, wherein the resultant ¹⁸F-TFB has a specific activity of at least 5 GBq/μmol.
 18. The method of claim 11, wherein an effective dose of ¹⁸F-tetrafluoroborate is about 0.036 mSv/MBq in males and about 0.064 mSv/MBq in females.
 19. The method of claim 11, wherein the ¹⁸F-tetrafluoroborate has a specific activity of at least 5 GBq/μmol.
 20. The method of claim 11, wherein the ¹⁸F-tetrafluoroborate has a specific activity of at least 8 GBq/μmol. 